Antikoagülan ve Antiagregan İlaçların Genel Komplikasyonları
Özet
Antiagregan ve antikoagulan ilaçlar kardiyovasküler hastalıkların tedavi ve proflaksisinde yaygın olarak kullanılmaktadır. Bu grup ilaçlar kullanılırken kanama gibi istenmeyen etkiler görülebilmesine rağmen ilaçların kullanılması hayati önem arz etmektedir. Bu bölümde antikoagulan ve antaigregan ilaçların en sık görülen yan etkilerinden bahsedilecektir.
Antiplatelet and anticoagulant drugs are widely used in the treatment and prophylaxis of cardiovascular diseases. Although side effects such as bleeding may be observed when using this group of drugs, the use of the drugs is of vital importance. In this section, the most common side effects of anticoagulant and antiplatelet drugs will be discussed.
Referanslar
Gîrleanu I, Alexandrescu DM, Petris A, Costache, II. Barriers of antiaggregant treatment. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2014;118(2):333-8.
Törüner M. Aspirin and gastrointestinal toxicity. Anatolian Journal of Cardiology/Anadolu Kardiyoloji Dergisi. 2007;7.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505-16.
Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-64.
Aksoy F, Baş HA, Bağcı A, Uysal BA, Aksoy S, Varol E, et al. Isparta ve çevresinde klopidogrel direncinin araştırılması. Medical Journal of Süleyman Demirel University. 2019;26(4):416-22.
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022;11(20).
Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. 5. Identification and synthesis of the hemorrhagic agent. 1941.
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527-39.
Srinivasan S, Ajmal M, Pecci C, Lassar T. Edoxaban in cardiovascular disease management: Review. British journal of clinical pharmacology. 2022;88(2):535-40.
Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. Journal of the American Heart Association. 2016;5(6):e003725.
Chan-Tack KM. Fatal spontaneous retroperitoneal hematoma secondary to enoxaparin. Southern medical journal. 2003;96(1):58-60.
Van Savage JG, Fried FA. Anticoagulant associated hematuria: a prospective study. The Journal of urology. 1995;153(5):1594-6.
Schuster GA, Lewis GA. Clinical significance of hematuria in patients on anticoagulant therapy. The Journal of urology. 1987;137(5):923-5.
Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Archives of internal medicine. 1994;154(6):649-52.
Barkin M, Lopatin W, Herschorn S, Comisarow R. Unexplained hematuria. Canadian Journal of surgery Journal Canadien de Chirurgie. 1983;26(6):501-3.
Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology. 2000;55(1):22-4.
Jeong CW, Lee S, Byun S-S, Lee DH, Lee SE. No increase in risk of microscopic hematuria with aspirin use by asymptomatic healthy people. JAMA internal medicine. 2013;173(12):1145-6.
Referanslar
Gîrleanu I, Alexandrescu DM, Petris A, Costache, II. Barriers of antiaggregant treatment. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2014;118(2):333-8.
Törüner M. Aspirin and gastrointestinal toxicity. Anatolian Journal of Cardiology/Anadolu Kardiyoloji Dergisi. 2007;7.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505-16.
Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-64.
Aksoy F, Baş HA, Bağcı A, Uysal BA, Aksoy S, Varol E, et al. Isparta ve çevresinde klopidogrel direncinin araştırılması. Medical Journal of Süleyman Demirel University. 2019;26(4):416-22.
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022;11(20).
Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. 5. Identification and synthesis of the hemorrhagic agent. 1941.
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527-39.
Srinivasan S, Ajmal M, Pecci C, Lassar T. Edoxaban in cardiovascular disease management: Review. British journal of clinical pharmacology. 2022;88(2):535-40.
Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. Journal of the American Heart Association. 2016;5(6):e003725.
Chan-Tack KM. Fatal spontaneous retroperitoneal hematoma secondary to enoxaparin. Southern medical journal. 2003;96(1):58-60.
Van Savage JG, Fried FA. Anticoagulant associated hematuria: a prospective study. The Journal of urology. 1995;153(5):1594-6.
Schuster GA, Lewis GA. Clinical significance of hematuria in patients on anticoagulant therapy. The Journal of urology. 1987;137(5):923-5.
Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Archives of internal medicine. 1994;154(6):649-52.
Barkin M, Lopatin W, Herschorn S, Comisarow R. Unexplained hematuria. Canadian Journal of surgery Journal Canadien de Chirurgie. 1983;26(6):501-3.
Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology. 2000;55(1):22-4.
Jeong CW, Lee S, Byun S-S, Lee DH, Lee SE. No increase in risk of microscopic hematuria with aspirin use by asymptomatic healthy people. JAMA internal medicine. 2013;173(12):1145-6.
